# BIOG keeps its focus on small-cap biotech and M&A potential

- Link: https://www.directorstalkinterviews.com/biog-keeps-its-focus-on-small-cap-biotech-and-ma-potential/4121260702
- Published: 2026-08-19T10:35:00+01:00
- Author: Amilia Stone

BIOG’s latest portfolio update points to a simple message: despite a strong rise
in the shares, the managers still see meaningful value in the portfolio.

The shares have more than doubled since 2025, while the portfolio is still considered
cheap. That matters because the current strategy is not built around chasing past
gains. The managers remain focused on areas where they believe valuations still 
leave room for further upside.

Over the last 12 months, BIOG delivered a net asset value total return of 87.0% 
and a share price total return of 95.8%. The strength was not limited to one part
of the portfolio. Performance was broad-based across different therapeutic areas
and across companies at different stages of development.

That breadth is important in biotechnology, where individual companies can be highly
dependent on clinical progress, regulatory outcomes or commercial execution. A wider
spread of holdings helps reduce reliance on any single programme or therapeutic 
theme.

BIOG also continues to run an overweight position in small-cap biotechnology. This
remains the area where the managers see the greatest upside potential.

Smaller biotech companies can carry higher development and financing risks, but 
they can also offer more substantial rerating potential when clinical results improve,
strategic interest increases or market expectations change. BIOG’s positioning suggests
the managers believe the risk-reward remains attractive despite the sector’s recent
gains.

The portfolio remains positioned around three main drivers: continued progress across
a broad range of biotechnology companies, further upside from small-cap valuations,
and the possibility of additional M&A activity.

_**Biotech Growth Trust plc** (LON:BIOG) seeks capital appreciation through investment
in the worldwide biotechnology industry. The Company and the Company’s Portfolio
Manager believe that there is a high congruence between companies that seek to act
responsibly and those that succeed in building long-term shareholder value. _

Share on:
